Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 87.06% is in line with its 5-year average of 83.71%, near the high end of its 5-year range (70.53%–88.39%).
0.03% below its 12-month average of 87.09%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 86.53%.
GROSS MARGIN
87.06%
GROSS MARGIN AVG TTM
87.09%
GROSS MARGIN AVG 3Y
85.74%
GROSS MARGIN AVG 5Y
83.71%
GROSS MARGIN AVG 10Y
70.80%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.03%
CURRENT VS 3Y AVG
+1.54%
CURRENT VS 5Y AVG
+4.00%
CURRENT VS 10Y AVG
+22.96%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+111.29%
vs the sector median at left
electroCore, Inc.
Market Cap
$89.44M
Gross Margin
87.06%
TTM Avg
87.09%
3Y Avg
85.74%
5Y Avg
83.71%
Market Cap
$90.20M
Gross Margin
40.32%
TTM Avg
35.69%
3Y Avg
34.43%
5Y Avg
37.90%
Market Cap
$90.64M
Gross Margin
89.28%
TTM Avg
-3011.26%
3Y Avg
-1505.63%
5Y Avg
-1003.75%
Market Cap
$87.85M
Gross Margin
82.44%
TTM Avg
83.07%
3Y Avg
-40.55%
5Y Avg
-241.44%
Market Cap
$87.27M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$85.86M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| electroCore, Inc. (ECOR) | $89.44M | 87.06% | 87.09% | 85.74% | 83.71% |
| Equillium, Inc. (EQ)vs › | $89.78M | 0.00% | 50.00% | 75.00% | 50.00% |
| ImmuCell Corporation (ICCC)vs › | $90.20M | 40.32% | 35.69% | 34.43% | 37.90% |
| Biomea Fusion, Inc. (BMEA)vs › | $90.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| Rallybio Corporation (RLYB)vs › | $90.64M | 89.28% | -3011.26% | -1505.63% | -1003.75% |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 46.51% | 45.81% | 42.58% | 41.06% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $87.85M | 82.44% | 83.07% | -40.55% | -241.44% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $87.27M | 0.00% | 0.00% | 0.00% | 0.00% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $85.86M | 0.00% | 0.00% | 0.00% | 0.00% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $93.96M | 10.89% | 14.00% | 13.41% | 13.41% |
Gross Margin
87.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 86.53% |
| 2026-03-31 | 87.27% |
| 2025-12-31 | 88.39% |
| 2025-09-30 | 85.97% |
| 2025-06-30 | 87.28% |
| 2025-03-31 | 84.92% |
| 2024-12-31 | 85.89% |
| 2024-09-30 | 83.75% |
| 2024-06-30 | 86.35% |
| 2024-03-31 | 83.69% |
| 2023-12-31 | 78.81% |
| 2023-09-30 | 85.34% |
| 2023-06-30 | 83.53% |
| 2023-03-31 | 83.53% |
| 2022-12-31 | 75.00% |
| 2022-09-30 | 86.94% |
| 2022-06-30 | 83.40% |
| 2022-03-31 | 81.04% |
| 2021-12-31 | 80.43% |
| 2021-09-30 | 76.13% |
| 2021-06-30 | 70.53% |
| 2021-03-31 | 69.77% |
| 2020-12-31 | 11.78% |
| 2020-09-30 | 67.85% |
| 2020-06-30 | 63.74% |
| 2020-03-31 | 59.37% |
| 2019-12-31 | 42.10% |
| 2019-09-30 | 48.18% |
| 2019-06-30 | 59.15% |
| 2019-03-31 | 61.48% |
| 2018-12-31 | 47.70% |
| 2018-09-30 | 35.71% |
| 2018-06-30 | 38.93% |
| 2018-03-31 | 39.71% |
| 2017-12-31 | -18.74% |
| 2017-09-30 | 54.70% |
| 2017-06-30 | 78.05% |
| 2017-03-31 | 37.79% |
